Literature DB >> 2627742

Ranitidine in the treatment of reflux oesophagitis in pregnancy.

G Armentano1, P L Bracco, C Di Silverio.   

Abstract

A patient suffering from reflux oesophagitis under treatment with ranitidine continued the treatment throughout her pregnancy (450 mg/die). The ranitidine was delivered into the maternal blood serum and the amniotic fluid up to the 17th week of pregnancy, then into the blood serum of the maternal and umbilical cord immediately after delivery, and into the serum of the newborn 24 hours after birth. The authors report the values and comment on them.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2627742

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  2 in total

1.  Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study.

Authors:  L A Magee; G Inocencion; L Kamboj; F Rosetti; G Koren
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 2.  Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options?

Authors:  C N Broussard; J E Richter
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.